ArticleCell reports. Medicine2025
Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity.
Abstract read
In one paragraph
Article in Cell reports. Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- DNA-based vaccines: Advances, applications, and future prospects.Genes & diseases · 2026Review
- Therapeutic cancer vaccines: development, challenges, and future perspectives.Acta pharmacologica Sinica · 2026Review
- Focused ultrasound-mediated lipid nanoparticle delivery for brain gene editing.Molecular therapy. Nucleic acids · 2026Article
- Overcoming size barriers in retinal gene therapy via lipid nanoparticle-mediated delivery of full-length eys DNA.Drug delivery and translational research · 2026Article
- Immune protection in chickens via lipid nanoparticle-encapsulated VP2 DNA vaccine against very virulent infectious bursal disease virus.Poultry science · 2026Article
- Advancements in nanomaterial-based adjuvants for animal vaccines.Materials today. Bio · 2026Article
- Ultrasound-activated piezoelectric Bi@Bi-MOF enables STING-mediated immunotherapy for implant-associated infections.Journal of nanobiotechnology · 2026Article
- Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic.Journal for immunotherapy of cancer · 2026Article
- From RNA to DNA: How Cargo Identity Reprograms Lipid Nanoparticle Architecture and Function.Advanced healthcare materials · 2026Review
- A low-toxicity circular single-stranded DNA platform for safe and potent IL-12 immunotherapy against hepatocellular carcinoma.Journal of nanobiotechnology · 2026Article
- DNA delivered by lipid nanoparticles induces CD8+ T cell-dependent antitumor responses and enhances anti-PD-L1 therapy.JCI insight · 2026Article
- Myomerger-derived peptide enhances skeletal muscle tropism and reduces liver transduction of lipid nanoparticles for gene delivery.Molecular therapy. Nucleic acids · 2026Article
- Nanoparticle Immunoadjuvant Complexes Augment Germinal Center Responses to Vaccination.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Varicella Zoster Virus Infection: Clinical Features, Molecular Pathogenesis, Treatment, and Prevention.MedComm · 2026Review
- Review
- Mesenchymal Stem Cell-Inspired Microneedle Platform for NIR-responsive Immunomodulation and Accelerated Chronic Wound Healing.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Durability of DNA-LNP and mRNA-LNP vaccine-induced immunity against SARS-CoV-2 XBB.1.5.NPJ vaccines · 2026Article
- Article
- Multi-antigen DNA vaccine targeting non-structural proteins confers robust T Cell-mediated protection against Zika virus.NPJ vaccines · 2026Article
- Electroporation and LNP-mediated delivery of plasmid DNA-encoded H5N1 influenza virus hemagglutinin support protection against highly pathogenic avian influenza.NPJ vaccines · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Nicholas J TursiVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Sachchidanand TiwariDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Nicole BedanovaVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Toshitha KannanVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Elizabeth ParzychVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Nisreen OkbaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Kevin LiawVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
András SárközyDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Cory LivingstonVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Maria Ibanez TrullenDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
Ebony N GaryVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Máté VadovicsDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Niklas LaengerVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA; Biology Department, Saint Joseph's University, Philadelphia, PA 19131, USA.
Jennifer LondreganPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Mohammad Suhail KhanVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Serena Omo-LamaiDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Hiromi MuramatsuDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Kerry BlatneyVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Casey HojeckiVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Viviane MachadoInovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
Igor MaricicInovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
Trevor R F SmithInovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
Laurent M HumeauInovio Pharmaceuticals, Plymouth Meeting, PA 19462, USA.
Ami PatelVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Andrew KossenkovVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA.
Jacob S BrennerDepartment of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
David AllmanPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Florian KrammerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna, Vienna, Austria.
Norbert PardiDepartment of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. Electronic address: pnorbert@pennmedicine.upenn.edu.
David B WeinerVaccine and Immunotherapy Center, The Wistar Institute, Philadelphia, PA 19104, USA. Electronic address: dweiner@wistar.org.
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Nan Zhang · 1985 to 2026
$75.9MTRAINING PROGRAM IN BASIC CANCER RESEARCHT32CA009171 · NCI · WISTAR INSTITUTE · PI Alessandro Gardini · 1985 to 2026
$15.3MNotch2 Amplification of B Cell Division and Differentiation FatesF31AI179166 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI LONDREGAN, JENNIFER · 2024 to 2025
$74kNCI NIH HHS P30 CA010815NCI NIH HHS T32 CA009171NIAID NIH HHS F31 AI179166
Abstract
Nucleic acid vaccines have grown in importance over the past several years, with the development of new approaches remaining a focus. We describe a lipid nanoparticle-formulated DNA (DNA-LNP) formulation which induces robust innate and adaptive immunity with similar serological potency to mRNA-LNPs and adjuvanted protein. Using an influenza hemagglutinin (HA)-encoding construct, we show that priming with our HA DNA-LNP demonstrated stimulator of interferon genes (STING)-dependent upregulation and activation of migratory dendritic cell (DC) subpopulations. HA DNA-LNP induced superior antigen-specific CD8
Indexed as
Adaptive ImmunityImmunity, InnateLipidsNanoparticlesPlasmidsVaccines, DNAAdjuvants, ImmunologicAnimalsCD8-Positive T-LymphocytesCOVID-19COVID-19 VaccinesDendritic CellsFemaleHemagglutinin Glycoproteins, Influenza VirusHumansLiposomesAdjuvants, ImmunologicCOVID-19 VaccinesHemagglutinin Glycoproteins, Influenza VirusLipid NanoparticlesLipidsLiposomesSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Vaccines, DNAadjuvanted proteinantibodyDNA-LNPlipid nanoparticlemRNAplasmid DNAT cellvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.